Autochthonous dengue outbreak in Northern Italy, September 2024: epidemiological, microbiological, entomological investigation and public health response Jasleen Singh, Tiziana Lazzarotto, Christina Merakou, Giada Rossini, Maurilia Marcacci, Guido Di Donato, Rodolfo Veronesi, Antonino Bella, Giulietta Venturi, Marco Di Luca, Arianna Puggioli, Ilaria Pati, Raffaele Donadio, Rino Biguzzi, Nicola Alvaro, Alessandra Fantuzzi, Flavia Riccardo, Giacomo Creola, Paola Angelini, Giulio Matteo, Mattia Calzolari, Michele Dottori, Patrizio Pezzotti, Chiara Sacco, Martina Del Manso, Francesco Severini, Luciano Toma, Caterina Vocale, Silvia Galli, Liliana Gabrielli, Greta Roncarati, Giulia Piccirilli, Simona Venturoli, Evangelia Petrisli, Giorgio Gallinella, Luca Ruotolo, Beatrice Mola, Isabella Bon, Margherita Ortalli, Fabrizia Valleriani, Angela Taraschi, Chiara Pinoni, Barbara Secondini, Valeria Di Lollo, Alessandro Albieri, Romeo Bellini, Marco Carrieri, Roberta Colonna, Luciano Donati, Debora Ruggeri, Sabina Sanseverinati, Elisabetta Fioretti, Barbara Mai, Carmela Palomba, Miriam Benatti, Giuseppe Diegoli, Giovanna Mattei, Stefano Benedetti, Cristina Liverani, Monica Soracase, Esther Rita De Gioia, Claudio Gualanduzzi, Cinzia Perilli, Alessia Leucci, Annalisa Grisendi, Mara Scremin, Katia Marzani, Deborah Torri, Letizia Lombardini Travel Medicine and Infectious Disease, 2026 BACKGROUND: Dengue is an emerging public health threat in temperate regions of Europe where Aedes albopictus is established. In 2024 Italy experienced an unprecedented increase in autochthonous dengue transmission. In September 2024, a cluster of locally acquired dengue cases was detected in Cavezzo, Emilia-Romagna, Northern Italy. METHODS: An outbreak investigation was initiated following confirmation of the first autochthonous dengue case on 17 September 2024. Enhanced surveillance was activated including retrospective case finding, targeted community screening, and strengthened laboratory diagnostics. Vector control measures were implemented starting within a 200m radius of confirmed cases and expanded based on epidemiological and entomological findings. Blood and organ donation safety measures were introduced, and whole genome sequencing were performed on human and mosquito samples. RESULTS: 44 autochthonous dengue cases were identified with symptom onset between 31 July and 23 September 2024; 68.2% were detected retrospectively. No epidemiologically linked cases were detected outside Cavezzo. Most cases occurred in older adults (median age 63 years); two patients were hospitalised and recovered fully. Dengue virus serotype 2 (DENV-2), genotype II, lineage F.1.1, was detected in both human and Ae. albopictus samples. Phylogenetic analysis identified a distinct cluster separate from sequences associated with the contemporaneous outbreak reported in Fano, Italy. Following vector-control interventions, mosquito density declined and no further virus-positive pools were detected. CONCLUSION: This outbreak highlights the increasing vulnerability of temperate European regions to dengue transmission and underscores the importance of rapid case detection, community engagement, and targeted vector-control strategies in preventing wider spread.
A Comprehensive Analysis of Diagnostic and Virological Surveillance During the 2023–2025 Measles Epidemic Scenario Martina Franceschiello, Martina Tamburello, Giulia Piccirilli, Eva Caterina Borgatti, Federica Lanna, Alessia Bertoldi, Simona Venturoli, Giada Rossini, Silvia Gioacchini, Melissa Baggieri, Fabio Magurano, Michela Morri, Giulio Matteo, Christian Cintori, Giovanna Mattei, Vittorio Lodi, Liliana Gabrielli, Tiziana Lazzarotto Diagnostics, 2026 Background/Objectives: Since 2023, a significant increase in measles cases has been reported worldwide, and Italy has been among the most affected European countries. In this context, the integration of laboratory and epidemiological data enables timely case classification and helps distinguish between imported and indigenous cases, supporting disease control. However, most studies address only selected aspects of surveillance. Therefore, this study aimed to provide an integrated analysis of virological and epidemiological surveillance activities conducted between November 2023 and December 2025 by the Regional Reference Laboratory in the Emilia-Romagna Region (ERR). Methods: A total of 806 clinical samples (269 urine, 267 oral fluids—saliva or oropharyngeal swabs—and 270 sera) from 291 suspected measles cases were tested by molecular and/or serological methods, and MV genotyping was performed. Samples from discarded cases were also analysed for parvovirus B19 (B19V), human herpesvirus 6 (HHV-6), enterovirus (EV), and varicella zoster virus (VZV), chikungunya virus (CHIKV) and dengue virus (DENV). Results: Of 291 suspected cases, 176 (60.5%) were confirmed. Median age was 33 years, with 46% in the 15–39 year group. Vaccination status was available for 165: 90.3% were unvaccinated, 5.4% had one dose, and 4.2% had two doses. Notably, over half of confirmed cases occurred in areas with vaccine-hesitant communities. MV strain characterisation was performed in 99.4% of MV-RNA positive cases, with 84.3% genotype D8 and 15.6% genotype B3; 83% of strains were of indigenous origin, suggesting an ongoing endemic circulation. Clinical data showed complications in 19.3%, mainly pneumonia and diarrhoea. Additionally, differential diagnosis enabled the identification of the etiological agent in 37.5% of measles/rubella discarded cases, and 37.6% (29/77) tested positive for B19V. Conclusions: The study results highlight that effective measles surveillance must be supported by integrating timely virological diagnosis, molecular and epidemiological investigations, and differential diagnosis, to achieve the WHO goals of eliminating measles transmission.
Understanding the evolutionary dynamics of Monkeypox virus through less explored pathways Alessandra Mistral De Pascali, Ludovica Ingletto, Martina Brandolini, Ettore Rocchi, Martina Tarozzi, Maria Elena Turba, Rita Casadio, Fabio Gentilini, Giulia Gatti, Laura Dionisi, Claudia Colosimo, Massimiliano Guerra, Silvia Zannoli, Giorgio Dirani, Maria Sofia Montanari, Anna Marzucco, Laura Grumiro, Giada Rossini, Tiziana Lazzarotto, Monica Cricca, Gastone Castellani, Vittorio Sambri, Alessandra Scagliarini Scientific Reports, 2025 Recent Monkeypox virus (MPXV) outbreaks in non-endemic regions have highlighted the need for genomic surveillance to support epidemiological investigations and monitor viral evolution. In this paper we present the results of genomic characterization and analyses of mechanisms of human adaptation, including APOBEC-style mutations, performed on 11 MPXV isolates, collected from May to September 2022, from Emilia-Romagna (Italy). Phylogenetic analysis confirmed all strains belonged to Clade IIb. Viruses from male patients were classified within lineage B (sub-lineages B.1, B.1.3, B.1.12), while a strain from a female patient was assigned to lineage A (A.2.3), with epidemiological links to Ghana. This represents the fourth detection of an A.2.3 strain of African origin outside the continent. Disruptions were identified in two genes: OPG176 (similar to VACV-Cop A46R), as reported in lineage A, and OPG023 (similar to VACV-Cop D7L), resulting in protein truncation that may suggest a possible pattern of human adaptation. These findings further enhance our understanding of MPXV Clade IIb diversity through characterization of a rarer variant giving insights from a less explored epidemiological pathway.
JN.1 variants circulating in Italy from October 2023 to April 2024: genetic diversity and immune recognition Emanuela Giombini, Ilaria Schiavoni, Luigina Ambrosio, Alessandra Lo Presti, Angela Di Martino, Stefano Fiore, Pasqualina Leone, Francesca Fortunato, Rosa Prato, Giorgio Fedele, Anna Teresa Palamara, Paola Stefanelli, , Liborio Stuppia, Federico Anaclerio, Giovanni Savini, Cesare Cammà, Luigi Possenti, Domenico Dell’Edera, Antonio Picerno, Teresa Lopizzo, Maria Teresa Fiorillo, Rosaria Oteri, Giuseppe Viglietto, Pasquale Minchella, Francesca Greco, Antonio Limone, Giovanna Fusco, Claudia Tiberio, Luigi Atripaldi, Mariagrazia Coppola, Davide Cacchiarelli, Antonio Grimaldi, Stefano Pongolini, Erika Scaltriti, Vittorio Sambri, Giorgio Dirani, Silvia Zannoli, Tiziana Lazzarotto, Giada Rossini, Federica Baldan, Sabrina Lombino, Pierlanfranco D’Agaro, Ludovica Segat, Fabio Barbone, Raffaella Koncan, Antonio Battisti, Patricia Alba, Maria Teresa Scicluna, Silvia Angeletti, Elisabetta Riva, Fulvia Pimpinelli, Maurizio Fanciulli, Alice Massacci, Maurizio Sanguinetti, Fabrizio Maggi, Martina Rueca, Cesare Ernesto Maria Gruber, Ombretta Turriziani, Carlo Federico Perno, Francesca Ceccherini-Silberstein, Maria Concetta Bellocchi, Bianca Bruzzone, Giancarlo Icardi, Andrea Orsi, Rea Valaperta, Maria Oggionni, Sophie Testa, Fabio Sagradi, Arnaldo Caruso, Serena Messali, Diana Fanti, Alice Nava, Sergio Malandrin, Annalisa Cavallero, Claudio Francesco Farina, Marco Arosio, Ferruccio Ceriotti, Sara Colonia Uceda Renteria, Stefania Paganini, Anna Maria Di Blasio, Erminio Torresani, Maria Beatrice Boniotti, Cristina Bertasio, Nicola Clementi, Michela Sampaolo, Federica Novazzi, Nicasio Mancini, Maria Rita Gismondo, Valeria Micheli, Fausto Baldanti, Federica AM Giardina, Antonio Piralla, Federica Zavaglio, Francesca Rovida, Elena Pariani, Cristina Galli, Laura Pellegrinelli, Stefano Menzo, Massimiliano Scutellà, Valentina Felice, Elisabetta Pagani, Irene Bianconi, Angela Maria Di Pierro, Lucia Collini, Giovanni Lorenzin, Valeria Ghisetti, Sara Gilardi, Alice Bartolini, Daniela Cantarella, Simone Peletto, Giuseppe Ru, Pier Luigi Acutis, Elena Bozzetta, Maria Chironna, Daniela Loconsole, Antonio Parisi, Fabio Arena, Rossella De Nittis, Giuseppina Iannelli, Florigio Romano Lista, Ferdinando Coghe, Sergio Uzzau, Salvatore Rubino, Flavia Angioj, Gabriele Ibba, Caterina Serra, Giovanna Piras, Giuseppe Mameli, Rosanna Asproni, Francesca Di Gaudio, Stefano Vullo, Stefano Reale, Teresa Pollicino, Francesco Vitale, Fabio Tramuto, Stefania Stefani, Guido Scalia, Concetta Ilenia Palermo, Giuseppe Mancuso, Vincenzo Bramanti, Carmelo Fidone, Giuseppe Barrano, Mauro Pistello, Gian Maria Rossolini, Francesca Malentacchi, Maria Grazia Cusi, Antonella Mencacci, Barbara Camilloni, Calogero Terregino, Alice Fusaro, Isabella Monne, Edoardo Giussani, Davide Gibellini, Emil Tonon, Riccardo Cecchetto, Laura Squarzon, Mosè Favarato, Valeria Biscaro, Elisa Vian, Silvia Ragolia, Michela Pascarella, Fabio Buffoli, Isabella Cerbaro BMC Infectious Diseases, 2025 BACKGROUND: The continuous emergence of SARS-CoV-2 variants and subvariants poses significant public health challenges. The latest designated subvariant JN.1, with all its descendants, shows more than 30 mutations in the spike gene. JN.1 has raised concerns due to its genomic diversity and its potential to enhance transmissibility and immune evasion. This study aims to analyse the molecular characteristics of JN.1-related lineages (JN.1*) identified in Italy from October 2023 to April 2024 and to evaluate the neutralization activity against JN.1 of a subsample of sera from individuals vaccinated with XBB.1.5 mRNA. METHODS: The genomic diversity of the spike gene of 794 JN.1* strain was evaluated and phylogenetic analysis was conducted to compare the distance to XBB.1.5. Moreover, serum neutralization assays were performed on a subsample of 19 healthcare workers (HCWs) vaccinated with the monovalent XBB.1.5 mRNA booster to assess neutralizing capacity against JN.1. RESULTS: Sequence analysis displayed high spike variability between JN.1* and phylogenetic investigation confirmed a substantial differentiation between JN.1* and XBB.1.5 spike regions with 29 shared mutations, of which 17 were located within the RBD region. Pre-booster neutralization activity against JN.1 was observed in 42% of HCWs sera, increasing significantly post-booster, with all HCWs showing neutralization capacity three months after vaccination. A significant correlation was found between anti-trimeric Spike IgG levels and neutralizing titers against JN.1. CONCLUSIONS: The study highlights the variability of JN.1* in Italy. Results on a subsample of sera from HCWs vaccinated with XBB.1.5 mRNA booster vaccine suggested enhanced neutralization activity against JN.1.
Investigating the evolutionary dynamics and mutational pattern of SARS-CoV-2 spike gene on selected SARS-CoV-2 variants Bachir Balech, Alessandra Lo Presti, Claudia Telegrafo, Lucia Maisto, Emanuela Giombini, Angela Di Martino, Luigina Ambrosio, Apollonia Tullo, Paola Stefanelli, and Plos One, 2025 The continuous evolution of SARS-CoV-2 has led to the emergence of several variants representing significant challenges for public health. Many studies highlight the relevance of phylogenetic inference or mutational pattern analysis to understand the evolutionary relatedness of viral variants and to estimate the potential effect of new mutations on viral transmission, virulence and antigenicity. Here we describe an evolutionary investigation approach combined with mutational analyses of SARS-CoV-2 Spike gene to annotate and potentially track important amino acid site variation of specific functional domain relevant for viral survival. This approach was applied on XBB*, EG* and BA* and their sub-lineages (see materials and methods) available from GISAID. In addition, we considered the major variants of concern (Alpha, Delta, Omicron) and Wuhan-Hu-1 strain as references. Maximum likelihood phylogenetic tree was constructed from the complete dataset while selection pressure and mutational analyses were conducted on single variants separately. The obtained phylogenetic tree of Spike amino acid gene sequence showed a clear separation of viral variants as well as their expected appearance order. This result supported the significance of selection pressure analyses outcomes combined with amino acid mutational frequencies where in many cases they showed a linear and parallel trend. This allowed also to hypothesize the potential importance of low-frequency mutations in new potential virus variants. This study constitutes an asset of important insights to be considered in regular monitoring programs. In addition, the analysis framework described here introduces a starting point for further standardization, optimization and application on different data types and in large-scale studies.
Virological findings in a case of travel-associated Oropouche virus (OROV) infection imported to Italy, June 2024 Giada Rossini, Beatrice Mola, Alessandra Rampini, Margherita Ortalli, Giovanna Mattei, Tiziana Lazzarotto Travel Medicine and Infectious Disease, 2025 Here we report the acute and post-acute virological findings in a OROV infected traveller returning to Italy from Cuba. Testing multiple specimen types and the prolonged detection of OROV RNA in whole blood and urine samples extend the possibility of cases confirmation through direct diagnosis even in convalescence-phase of infection. • Detection of OROV RNA in serum, plasma, whole blood and urine was examined. • Testing multiple specimen types is recommended to improve OROV RNA detection. • Testing whole blood and urine is useful in the convalescence-phase of OROV infection.
Auto-Abs neutralizing type I IFNs in patients with severe Powassan, Usutu, or Ross River virus disease Adrian Gervais, Paul Bastard, Lucy Bizien, Céline Delifer, Pierre Tiberghien, Chaturaka Rodrigo, Francesca Trespidi, Micol Angelini, Giada Rossini, Tiziana Lazzarotto, Francesca Conti, Irene Cassaniti, Fausto Baldanti, Francesca Rovida, Alessandro Ferrari, Davide Mileto, Alessandro Mancon, Laurent Abel, Anne Puel, Aurélie Cobat, Charles M. Rice, Dániel Cadar, Jonas Schmidt-Chanasit, Johannes F. Scheid, Jacob E. Lemieux, Eric S. Rosenberg, Marianna Agudelo, Stuart G. Tangye, Alessandro Borghesi, Guillaume André Durand, Emilie Duburcq-Gury, Braulio M. Valencia, Andrew R. Lloyd, Anna Nagy, Margaret M. MacDonald, Yannick Simonin, Shen-Ying Zhang, Jean-Laurent Casanova Journal of Experimental Medicine, 2024 Arboviral diseases are a growing global health concern. Pre-existing autoantibodies (auto-Abs) neutralizing type I interferons (IFNs) can underlie encephalitis due to West Nile virus (WNV) (∼40% of patients) and tick-borne encephalitis (TBE, due to TBE virus [TBEV]) (∼10%). We report here that these auto-Abs can also underlie severe forms of rarer arboviral infections. Auto-Abs neutralizing high concentrations of IFN-α2, IFN-β, and/or IFN-ω are present in the single case of severe Powassan virus (POWV) encephalitis studied, two of three cases of severe Usutu virus (USUV) infection studied, and the most severe of 24 cases of Ross River virus (RRV) disease studied. These auto-Abs are not found in any of the 137 individuals with silent or mild infections with these three viruses. Thus, auto-Abs neutralizing type I IFNs underlie an increasing list of severe arboviral diseases due to Flaviviridae (WNV, TBEV, POWV, USUV) or Togaviridae (RRV) viruses transmitted to humans by mosquitos (WNV, USUV, RRV) or ticks (TBEV, POWV).
Case reports of persistent SARS-CoV-2 infection outline within-host viral evolution in immunocompromised patients Luca Ruotolo, Silvia Silenzi, Beatrice Mola, Margherita Ortalli, Tiziana Lazzarotto, Giada Rossini Virology Journal, 2024 BACKGROUND: SARS-CoV-2 is responsible for the ongoing global pandemic, and the continuous emergence of novel variants threatens fragile populations, such as immunocompromised patients. This subgroup of patients seems to be seriously affected by intrahost viral changes, as the pathogens, which are keen to cause replication inefficiency, affect the impaired immune system, preventing efficient clearance of the virus. Therefore, these patients may represent an optimal reservoir for the development of new circulating SARS-CoV-2 variants. The following study aimed to investigate genomic changes in SARS-CoV-2-positive immunocompromised patients over time. METHODS: SARS-CoV-2-positive nasopharyngeal swabs were collected at different time points for each patient (patient A and patient B), extracted and then analyzed through next-generation sequencing (NGS). The resulting sequences were examined to determine mutation frequencies, describing viral evolution over time. CASE PRESENTATION: Patient A was a 53-year-old patient with onco-hematological disease with prolonged infection lasting for 51 days from May 28th to July 18th, 2022. Three confirmed SARS-CoV-2-positive samples were collected on May 28th, June 15th and July 4th. Patient B was 75 years old and had onco-hematological disease with prolonged infection lasting for 146 days. Two confirmed positive SARS-CoV-2 samples were collected at the following time points: May 21st and August 18th. CONCLUSION: Heat map construction provided evidence of gain and/or loss of mutations over time for both patients, suggesting within-host genomic evolution of the virus. In addition, mutation polymorphisms and changes in the SARS-CoV-2 lineage were observed in Patient B. Sequence analysis revealed high mutational pattern variability, reflecting the high complexity of viral replication dynamics in fragile patients.
Oropouche fever cases diagnosed in Italy in two epidemiologically non-related travellers from Cuba, late May to early June 2024 Concetta Castilletti, Antonio Mori, Andrea Matucci, Niccolò Ronzoni, Lukas Van Duffel, Giada Rossini, Pietro Sponga, Maria Luca D’Errico, Paola Rodari, Francesco Cristini, Ralph Huits, Federico Giovanni Gobbi Eurosurveillance, 2024 Oropouche fever is caused by Oropouche virus (OROV), transmitted primarily through the bite of infected midges, particularly of the genus Culicoides. The virus is mainly circulating in Central and South America where several countries reported an ongoing outbreak. We report here two imported cases of OROV infection identified in Italy, late May–early June 2024. These cases indicate that in the shadow of a massive dengue outbreak in the Americas, the Oropouche outbreak might be more widespread than previously estimated.
Autoantibodies neutralizing type I IFNs underlie West Nile virus encephalitis in ∼40% of patients Adrian Gervais, Francesca Rovida, Maria Antonietta Avanzini, Stefania Croce, Astrid Marchal, Shih-Ching Lin, Alessandro Ferrari, Christian W. Thorball, Orianne Constant, Tom Le Voyer, Quentin Philippot, Jérémie Rosain, Micol Angelini, Malena Pérez Lorenzo, Lucy Bizien, Cristian Achille, Francesca Trespidi, Elisa Burdino, Irene Cassaniti, Daniele Lilleri, Chiara Fornara, José Camilla Sammartino, Danilo Cereda, Chiara Marrocu, Antonio Piralla, Chiara Valsecchi, Stefano Ricagno, Paola Cogo, Olaf Neth, Inés Marín-Cruz, Monia Pacenti, Alessandro Sinigaglia, Marta Trevisan, Andrea Volpe, Antonio Marzollo, Francesca Conti, Tiziana Lazzarotto, Andrea Pession, Pierluigi Viale, Jacques Fellay, Stefano Ghirardello, Mélodie Aubart, Valeria Ghisetti, Alessandro Aiuti, Emmanuelle Jouanguy, Paul Bastard, Elena Percivalle, Fausto Baldanti, Anne Puel, Margaret R. MacDonald, Charles M. Rice, Giada Rossini, Kristy O. Murray, Yannick Simonin, Anna Nagy, Luisa Barzon, Laurent Abel, Michael S. Diamond, Aurélie Cobat, Shen-Ying Zhang, Jean-Laurent Casanova, Alessandro Borghesi Journal of Experimental Medicine, 2023 Mosquito-borne West Nile virus (WNV) infection is benign in most individuals but can cause encephalitis in <1% of infected individuals. We show that ∼35% of patients hospitalized for WNV disease (WNVD) in six independent cohorts from the EU and USA carry auto-Abs neutralizing IFN-α and/or -ω. The prevalence of these antibodies is highest in patients with encephalitis (∼40%), and that in individuals with silent WNV infection is as low as that in the general population. The odds ratios for WNVD in individuals with these auto-Abs relative to those without them in the general population range from 19.0 (95% CI 15.0–24.0, P value <10–15) for auto-Abs neutralizing only 100 pg/ml IFN-α and/or IFN-ω to 127.4 (CI 87.1–186.4, P value <10–15) for auto-Abs neutralizing both IFN-α and IFN-ω at a concentration of 10 ng/ml. These antibodies block the protective effect of IFN-α in Vero cells infected with WNV in vitro. Auto-Abs neutralizing IFN-α and/or IFN-ω underlie ∼40% of cases of WNV encephalitis.
Case report of Usutu virus infection in an immunocompromised patient in Italy, 2022 Paolo Gaibani, Nicole Barp, Marco Massari, Emanuele Alberto Negri, Giada Rossini, Caterina Vocale, Chiara Trenti, Altea Gallerani, Samuele Cantergiani, Federico Romani, Mattia Simion, Cristina Mussini, Tiziana Lazzarotto Journal of Neurovirology, 2023
Tracking the progressive spread of the SARS-CoV-2 Omicron variant in Italy, December 2021 to January 2022 Paola Stefanelli, Filippo Trentini, Daniele Petrone, Alessia Mammone, Luigina Ambrosio, Mattia Manica, Giorgio Guzzetta, Valeria d'Andrea, Valentina Marziano, Agnese Zardini, Carla Molina Grane’, Marco Ajelli, Angela Di Martino, Flavia Riccardo, Antonino Bella, Monica Sane Schepisi, Francesco Maraglino, Piero Poletti, Anna Teresa Palamara, Silvio Brusaferro, Giovanni Rezza, Patrizio Pezzotti, Stefano Merler, , and Eurosurveillance, 2022
Development and validation of a prediction model for severe respiratory failure in hospitalized patients with SARS-CoV-2 infection: a multicentre cohort study (PREDI-CO study) Michele Bartoletti, Maddalena Giannella, Luigia Scudeller, Sara Tedeschi, Matteo Rinaldi, Linda Bussini, Giacomo Fornaro, Renato Pascale, Livia Pancaldi, Zeno Pasquini, Filippo Trapani, Lorenzo Badia, Caterina Campoli, Marina Tadolini, Luciano Attard, Massimo Puoti, Marco Merli, Cristina Mussini, Marianna Menozzi, Marianna Meschiari, Mauro Codeluppi, Francesco Barchiesi, Francesco Cristini, Annalisa Saracino, Alberto Licci, Silvia Rapuano, Tommaso Tonetti, Paolo Gaibani, Vito M. Ranieri, Pierluigi Viale, Luigi Raumer, Luca Guerra, Fabio Tumietto, Alessandra Cascavilla, Eleonora Zamparini, Gabriella Verucchi, Simona Coladonato, Arianna Rubin, Stefano Ianniruberto, Eugenia Francalanci, Francesca Volpato, Giulio Virgili, Nicolò Rossi, Elena Rosselli Del Turco, Viola Guardigni, Giovanni Fasulo, Nicola Dentale, Ciro Fulgaro, Giorgio Legnani, Emanuele Campaci, Cristina Basso, Alberto Zuppiroli, Amalia Sanna Passino, Giulia Tesini, Lucia Angelelli, Adriana Badeanu, Agostino Rossi, Giulia Santangelo, Flovia Dauti, Vidak Koprivika, Nicholas Roncagli, Ioannis Tzimas, Guido Maria Liuzzi, Irid Baxhaku, Letizia Pasinelli, Mattia Neri, Tommaso Zanaboni, Francesco Dell'Omo, Oana Vatamanu, Alice Gori, Idina Zavatta, Stefano Antonini, Chiara Pironi, Elena Piccini, Luca Esposito, Alessandro Zuccotti, Giacomo Urbinati, Agnese Pratelli, Alberto Sarti, Michela Semprini, Enrico Evangelisti, Mara D'Onofrio, Giuseppe Sasdelli, Giacinto Pizzilli, Elisabetta Pierucci, Giada Rossini, Caterina Vocale, Lorenzo Marconi, Maria Cristina Leoni, Elisa Fronti, Giovanni Guaraldi, Davide Bavaro, Paola Laghetti Clinical Microbiology and Infection, 2020
Encephalopathy in COVID-19 Presenting With Acute Aphasia Mimicking Stroke Umberto Pensato, Lorenzo Muccioli, Elena Pasini, Maria Tappatà, Lorenzo Ferri, Lilia Volpi, Laura Licchetta, Stella Battaglia, Giada Rossini, Isabella Bon, Maria Carla Re, Luigi Cirillo, Luigi Simonetti, Laura Ludovica Gramegna, Roberto Michelucci, Pietro Cortelli, Andrea Zini, Francesca Bisulli Frontiers in Neurology, 2020
There is a role in detection of SARS-CoV-2 in conjunctiva and tears: A comprehensive review New Microbiologica, 2020
Specialist laboratory networks as preparedness and response tool - The emerging viral diseases-expert laboratory network and the chikungunya outbreak, Thailand, 2019 Giulietta Venturi, Stephan W Aberle, Tatjana Avšič-Županc, Luisa Barzon, Christoph Batejat, Elisa Burdino, Fabrizio Carletti, Rémi Charrel, Iva Christova, Jeff Connell, Victor Max Corman, Mary Emmanouil, Anne J Jääskeläinen, Ivan Kurolt, Yaniv Lustig, Miguel J Martinez, Marion Koopmans, Orsolya Nagy, Trung Nguyen, Anna Papa, Mercedes Pérez-Ruiz, Martin Pfeffer, Jelena Protic, Johan Reimerink, Giada Rossini, María Paz Sánchez-Seco Fariñas, Jonas Schmidt-Chanasit, Sandra Söderholm, Bertrand Sudre, Marjan Van Esbroeck,, Chantal B Reusken Eurosurveillance, 2020
New evidence of cutaneous leishmaniasis in north-eastern Italy V. Gaspari, M. Ortalli, M.P. Foschini, C. Baldovini, A. Lanzoni, R. Cagarelli, P. Gaibani, G. Rossini, C. Vocale, R. Tigani, G.A. Gentilomi, C. Misciali, S. Pesci, A. Patrizi, M.P. Landini, S. Varani Journal of the European Academy of Dermatology and Venereology, 2017
Human infection with highly pathogenic a(H7N7) avian influenza virus, Italy, 2013 Simona Puzelli, Giada Rossini, Marzia Facchini, Gabriele Vaccari, Livia Di Trani, Angela Di Martino, Paolo Gaibani, Caterina Vocale, Giovanni Cattoli, Michael Bennett, John W. McCauley, Giovanni Rezza, Maria Luisa Moro, Roberto Rangoni, Alba Carola Finarelli, Maria Paola Landini, Maria Rita Castrucci, Isabella Donatelli, and Emerging Infectious Diseases, 2014
Retrospective screening of serum and cerebrospinal fluid samples from patients with acute meningoencephalitis does not reveal past Japanese encephalitis virus infection, Emilia Romagna, Italy, 2011 Eurosurveillance, 2012
Blood culture systems: rapid detection--how and why? Paolo Gaibani, Giada Rossini, Simone Ambretti, Francesco Gelsomino, Anna Maria Pierro, Stefania Varani, Michela Paolucci, Maria Paola Landini, Vittorio Sambri International Journal of Antimicrobial Agents, 2009
Usutu virus infection in a patient who underwent orthotropic liver transplantation, Italy, August-September 2009. Euro Surveillance Bulletin Europeen Sur Les Maladies Transmissibles European Communicable Disease Bulletin, 2009
West Nile virus transmission with human cases in Italy, August - September 2009 Euro Surveillance Bulletin Europeen Sur Les Maladies Transmissibles European Communicable Disease Bulletin, 2009
The 2007 epidemic outbreak of Chikungunya virus infection in the Romagna region of Italy: A new perspective for the possible diffusion of tropical diseases in temperate areas? New Microbiologica, 2008
